AURA Earnings & Financial Statements
Aura Biosciences, Inc.
$7.14
-$0.47(-6.18%)
57
Overall
60
Value
90
Tech
21
Quality
Market Cap
$740.45M
Volume
533.81K
52W Range
$4.73 - $9.54
Target Price
$16.80
AURA earnings and financial statements: Aura Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AURA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$112.79M | -$96.12M | -$84.99M | -$60.30M | -$35.25M |
| EBITDA | -$111.66M | -$85.58M | -$74.98M | -$59.12M | -$34.41M |
| Net income | -$106.19M | -$86.92M | -$76.41M | -$58.76M | -$35.25M |
| EPS (diluted) | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-8.95 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $169.43M | $182.50M | $255.07M | $223.94M | $160.03M |
| Total liabilities | $32.52M | $30.53M | $29.23M | $28.35M | $7.71M |
| Shareholders’ equity | $136.91M | $151.97M | $225.85M | $195.58M | $152.31M |
| Cash and equivalents | $59.52M | $31.69M | $41.06M | $121.58M | $149.06M |
| Long-term debt | $14.13M | $15.62M | $16.87M | $17.89M | $360.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$84.74M | -$79.81M | -$63.85M | -$54.60M | -$32.41M |
| Capital expenditure | -$447.0K | -$1.25M | -$709.0K | -$1.09M | -$2.13M |
| Free cash flow | -$85.19M | -$81.06M | -$64.56M | -$55.70M | -$34.53M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AURA | $7.14 | -6.2% | 533.81K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |